Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-02-13
2009-12-08
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S268700
Reexamination Certificate
active
07629362
ABSTRACT:
The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I):[wherein X1represents a nitrogen atom, sulfur atom, oxygen atom or the like; R1represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R2and R3are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II)represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III)represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4404214 (1983-09-01), Takeda et al.
patent: 7390908 (2008-06-01), Boyd et al.
patent: 7432287 (2008-10-01), Iino et al.
patent: 7524957 (2009-04-01), Boyd et al.
patent: 2005/0080106 (2005-04-01), Boyd et al.
patent: 2006/0258701 (2006-11-01), Mitsuya et al.
patent: 2008/0207636 (2008-08-01), Boyd et al.
patent: 2 277 930 (1994-11-01), None
patent: 57-95984 (1982-06-01), None
patent: 58-121215 (1983-07-01), None
patent: 2002-47278 (2002-02-01), None
patent: WO 03/015774 (2003-02-01), None
patent: WO 2004/076420 (2004-09-01), None
patent: WO 2004/081001 (2004-09-01), None
Vippagunta et al., “Crystalline Solid”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Guillory (in Brittain ed.), “Polymorphism, etc.,” NY: Marcel Dekker, Inc., 1999, 1-2, 183-226.
D. Garfinkel et al., “Computer modeling identifies glucokinase as glucose sensor of pancreatic beta-cells”, American Journal Physiology, vol. 247, pp. 527-536 (1984).
A. Grupe et al., “Transgenic Knockouts Reveal a Critical Requirement for Pancreatic beta Cell Glucokinase in Maintaining Glucose Homeostasis”, Cell, vol. 83, pp. 69-78 (1995).
T. Ferre et al.m “Correction of diabetic alterations by glocokinase”, Proceedings of the National Academy of Sciences of the USA, vol. 93, pp. 7225-7230 (1996).
N. Vionnet et al., “Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus”, Nature, vol. 356, pp. 721-722 (1992).
B. Glaser et al., “Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation”, New England Journal of Medicine, vol. 338, pp. 226-230 (1998).
S. W. Kaldor et al., “Viracept (Nelfmavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease”, J. Med. Chem., vol. 40, pp. 3979-3985 (1997).
N. Zheng et al., “Palladium-Catalyzed Synthesis of Aryl Sulfides from Aryl Triflates”, J. Org. Chem., vol. 63, pp. 9606-9607 (1998).
G. Y. Li et al., “Highly Active, Air-Stable Versatile Palladium Catalysts for the C-C, C-N, and C-S Bond Formations via Cross-Coupling Reactions of Aryl Chlorides”, J. Org. Chem., vol. 66, pp. 8677-8681 (2001).
U. Schopfer et al., “A general palladium-catalysed synthesis of aromatic and heteroaromatic thioethers”, Tetrahedron, vol. 57, pp. 3069-3073 (2001).
T. Migita et al., “The Palladium Catalyzed Nucleophilic Substitution of Aryl Halides by Thiolate Anions”, Bull. Chem. Soc. Japan, vol. 53, pp. 1385-1389 (1980).
F. Y. Kwong et al., “A General, Efficient, and Inexpensive Catalyst System for the Coupling of Aryl Iodides adn Thiols”, Organic Letters, vol. 4, No. 20, pp. 3517-3520 (2002).
S. Rajagopalan et al., “Synthesis of N-t-BOC-4-S-t-Butyl-L-Thiophenylalanine Via Pallidium Catalyzed Cross-Coupling Reaction of N-t-BOC-4-IODO-L-Phenylalanine with t-Butylthiol or Sodium t-Butylthiolate”, Synthetic Communications, vol. 26, No. 7, pp. 1431-1440 (1996).
J. E. T. Corrie et al., “Synthesis of a Cephalosporin Analogue”, Journal of Chemical Society, Perkin Transaction, Chapter I, p. 1421-1425 (1977).
S. Sakakibara et al., “Use of Anhydrous Hydrogen Fluoride in Peptide Synthesis. I. Behavior of Various Protective Groups in Anhydrous Hydrogen Fluoride”, Bulletin of the Chemical Society of Japan, vol. 40, pp. 2164-2167 (1967).
D. A. J. Ives, “Electrolysis in liquid ammonia solution in peptide chemistry”, Canadian Journal of Chemistry, vol. 47, pp. 3697-3699 (1969).
A. Ogawa et al., “Highly Regio- and Stereocontrolled Synthesis of Vinyl Sulfides via Transition-Metal-Catalyzed Hydrothiolation of Alkynes with Thiols”, J. Am. Chem. Soc., vol. 121, pp. 5108-5114 (1999).
Bamba Makoto
Eiki Jun-ichi
Mitsuya Morihiro
Nishimura Teruyuki
Sakai Fumiko
Banyu Pharmaceutical Co. Ltd.
Billups Richard C.
Fitch Catherine D.
Morris Patricia L
LandOfFree
2-pyridine carboxamide derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-pyridine carboxamide derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-pyridine carboxamide derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084663